These profound differences in molecular drivers, metabolism, tumor microenvironment, and cellular functions highlight the need for distinct, side-specific therapeutic strategies, such as targeting the LPCAT2/ferroptosis axis or MMP7+ cells in LCRC, and glycolysis or hypoxia in RCRC. The gene discussed is LPCAT2; the disease is neoplasm.